Neurocrine Biosciences (NASDAQ: NBIX) Drives Growth with Strong Financials and Strategic Pipeline Expansion

Font: Financial Modeling Prep  • May 06, 2026

• Analyst Optimism: Piper Sandler raised its price target for Neurocrine Biosciences to $207, indicating a potential upside of 53.27% from its previous stock price.
• Robust Q1 2026 Performance: Neurocrine Biosciences significantly surpassed earnings estimates, reporting $1.94 per share against an estimated $1.68, alongside strong revenue of $814.5 million.
• Strategic Pipeline Expansion: The company is enhancing its portfolio through the acquisition of Soleno Therapeutics and advancing a Phase 2 clinical study for a new schizophrenia drug.

Neurocrine Biosciences (NASDAQ: NBIX) is a leading biopharmaceutical company that develops treatments for neurological and endocrine-related diseases. The company has a market capitalization of around $13.56 billion, which is the total market value of its outstanding shares. Neurocrine Biosciences focuses on creating medicines for conditions that have limited or no treatment options.

An analyst at Piper Sandler recently raised the price target for Neurocrine Biosciences to $207. At the time of the announcement, the stock’s price was $135.06, which suggests a potential increase of 53.27% if the target is met. This new target reflects a positive investment outlook on the company's future performance.

This optimism is supported by strong financial results. In its first quarter of 2026, Neurocrine Biosciences posted earnings of $1.94 per share, significantly beating estimates of $1.68, as highlighted by Zacks. This is a large increase from the $0.08 per share earned in the same quarter a year ago, showing substantial profit growth.

The company’s revenue also shows strong performance, reaching $814.5 million for the quarter and beating estimates. This growth is driven by net product sales of $811 million, a 44% increase from the previous year. Neurocrine Biosciences maintains its full-year sales forecast for its key drug, INGREZZA®, between $2.7 billion and $2.8 billion.

Future growth is also driven by strategic moves. As reported by PR Newswire, Neurocrine Biosciences announced an agreement to acquire Soleno Therapeutics, which adds a new treatment to its drug development portfolio. The company also started a Phase 2 clinical study for a new schizophrenia drug, expanding its development pipeline and potential future revenue sources.